Department of Paediatric Endocrinology & Metabolic Bone Diseases, Royal Manchester Children's Hospital, Oxford Road, Manchester, M13 9WL, UK.
Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham, B4 6NH, UK.
Orphanet J Rare Dis. 2018 Aug 16;13(1):142. doi: 10.1186/s13023-018-0869-4.
Hypophosphatasia (HPP) is a rare, heterogeneous disease caused by low tissue-nonspecific alkaline phosphatase activity and associated with a range of signs and symptoms, including bone mineralization defects, respiratory problems, seizures, premature tooth loss, and fractures. Data from patients with HPP and their healthcare resource utilization are lacking. We evaluated healthcare utilization for 3 patients with differing severities of HPP.
Patient 1 had perinatal HPP (received enzyme replacement therapy asfotase alfa under a compassionate use program), Patient 2 had infantile HPP, and Patient 3 had childhood HPP. Healthcare resources used in the National Health Service, England, were identified from coded activities in the hospital database and detailed medical records. These data showed that healthcare utilization was directly related to disease severity. Patient 1 had respiratory complications necessitating prolonged admission for ventilation from birth. Over 2.5 years, this patient was hospitalized 725 days, with visits from 16 specialists. Patient 2 had HPP-associated signs and symptoms starting in infancy, was treated for craniosynostosis, experienced multiple fractures, and required outpatient management for > 18 years. Patient 3 developed signs and symptoms of HPP in childhood and received outpatient and day case treatment for dental, orthopedic, and cardiovascular problems over 24 years. Healthcare utilization varied with severity and complexity of disease manifestations between these patients.
With the recent approval of asfotase alfa for HPP, data from this analysis may help mobilize multidisciplinary healthcare resources for management of HPP by elucidating healthcare resource needs of patients who show a spectrum of clinical manifestations of HPP.
低磷酸酯酶症(HPP)是一种罕见的、异质性疾病,由组织非特异性碱性磷酸酶活性降低引起,并伴有一系列的体征和症状,包括骨骼矿化缺陷、呼吸问题、癫痫发作、过早牙齿脱落和骨折。关于 HPP 患者及其医疗资源利用的数据尚缺乏。我们评估了 3 名具有不同严重程度 HPP 患者的医疗资源利用情况。
患者 1 患有围产期 HPP(根据同情用药计划接受阿法特酶替代治疗),患者 2 患有婴儿期 HPP,患者 3 患有儿童期 HPP。在英国国家医疗服务体系中使用的医疗资源是从医院数据库和详细病历中的编码活动中确定的。这些数据表明,医疗资源的利用与疾病的严重程度直接相关。患者 1 因呼吸并发症需要从出生起就进行长时间的通气住院治疗。在 2.5 年多的时间里,该患者住院 725 天,接受了 16 名专家的治疗。患者 2 在婴儿期出现与 HPP 相关的体征和症状,接受了颅缝早闭治疗,经历了多次骨折,并需要进行超过 18 年的门诊管理。患者 3 在儿童期出现 HPP 的体征和症状,在 24 年的时间里接受了口腔、骨科和心血管问题的门诊和日间手术治疗。这 3 名患者的医疗资源利用情况因疾病表现的严重程度和复杂性而异。
随着阿法特酶治疗 HPP 的近期获批,该分析的数据可能有助于通过阐明具有 HPP 多种临床表现的患者的医疗资源需求,为 HPP 的多学科医疗资源管理提供动力。